It was reported that on (b)(6) 2015, a 3.5x23mm xience v stent was implanted in the mid left anterior descending (lad) coronary artery.Following, a distal edge dissection was noted and treated with a 3.0x15mm xience v stent.Post procedure, the patient complained of non-cardiac chest pain and a headache.Medication was provided for both.Reportedly, the chest pain and headache were not serious.On (b)(6) 2015, the headache resolved without sequela and the patient was discharged home.There was no additional information provided.
|
(b)(4).Lab data: (b)(6) 2015 (12:15): troponin i=0.005 ng/ml, upper reference limit 0.04; (b)(6) 2015: ck=42 u/l, normal upper limit 223; (b)(6) 2015: ck-mb=1.3 ng/ml, normal upper limit 5.0.It is indicated that the device is not returning for evaluation; therefore, a failure analysis of the complaint device could not be completed.A review of the lot history record revealed no non-conformances that would have contributed to the reported event.The reported patient effects of pain, headache and dissection, as listed in the xience v everolimus eluting coronary stent system electronic instructions for use (ifu) are known patient effects that may be associated with the use of coronary stents.Although a conclusive cause for the reported patient effects, and the relationship to the product, if any, cannot be determined, there is no indication of a product quality deficiency with respect to manufacturing, design or labeling.Based on the reviewed information, no product deficiency was identified.
|